管理成年人与屏幕检测的小岛自身抗体阳性:一个务实的框架
Nicholas Thomas1, Danijela Tatovic2, Angus Jones1
1Institute of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK; Department of Diabetes and Endocrinology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
The lancet. Diabetes & endocrinology
|October 16, 2025
概括
新的疗法可以通过对岛屿自身抗体的查来延迟1型糖尿病的发病. 本指南为管理那些测试阳性但尚未被诊断为糖尿病的成年人提供了一个框架.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 公共卫生 公共卫生
背景情况:
- 改变疾病的疗法,如特普利祖马布,可以延迟1型糖尿病的临床发病.
- 岛屿自身抗体查可以识别有1型糖尿病高风险的个体.
- 临床医生面临的挑战是管理对岛屿自身抗体阳性但没有被诊断为糖尿病的成年人.
研究的目的:
- 为管理岛屿自身抗体阳性的成年人提供国际指导方针的明确性.
- 为这个不断增长的患者群体提出一个务实的管理框架.
- 为了解决成人1型糖尿病查计划管理中的不确定性.
主要方法:
- 国际共识指南的审查和综合.
- 对岛屿自身抗体阳性成年人临床管理挑战的分析.
- 为英国国家卫生服务设置开发一个务实的管理框架,适应其他系统.
主要成果:
- 与儿童相比,岛屿自身抗体阳性的成年人患1型糖尿病的进展风险较低.
- 在成年人中非自身免疫性失糖症的高患病率使管理复杂化.
- 一个拟议的框架为临床医生提供了实际指导.
结论:
- 有效管理成年人与岛屿自身抗体阳性需要量身定制的方法.
- 拟议的框架旨在改善临床决策和患者的治疗结果.
- 本指南适用于管理1型糖尿病查的各种医疗保健系统.
相关概念视频
Diabetes: Management and Pharmacotherapy
861
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
861
Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K
Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
Chronic Pancreatitis II: Collaborative Care
311
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
311
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Insulin: Dosing Regimen and Adverse Effects
677
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
677


